Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

被引：65
作者：
Fonseca, V. [1 ]
Baron, M. [2 ]
Shao, Q. [2 ]
Dejager, S. [2 ]
机构：
[1] Tulane Univ, Hlth Sci Ctr, Dept Endocrinol, New Orleans, LA 70112 USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
HORMONE AND METABOLIC RESEARCH | 2008年 / 40卷 / 06期
关键词：
D O I：
10.1055/s-2008-1058090
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：427 / 430
页数：4
相关论文
共 13 条
[1]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[2]   The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients [J].
Balas, Bogdan ;
Baig, Muhammad R. ;
Watson, Catherine ;
Dunning, Beth E. ;
Ligueros-Saylan, Monica ;
Wang, Yibin ;
He, Yan-Ling ;
Darland, Celia ;
Holst, Jens J. ;
Deacon, Carolyn F. ;
Cusi, Kenneth ;
Mari, Andrea ;
Foley, James E. ;
DeFronzo, Ralph A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04) :1249-1255
[3]   Mechanisms of the age-associated deterioration in glucose tolerance - Contribution of alterations in insulin secretion, action, and clearance [J].
Basu, R ;
Breda, E ;
Oberg, AL ;
Powell, CC ;
Dalla Man, C ;
Basu, A ;
Vittone, JL ;
Klee, GG ;
Arora, P ;
Jensen, MD ;
Toffolo, G ;
Cobelli, C ;
Rizza, RA .
DIABETES, 2003, 52 (07) :1738-1748
[4]   Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].
Bosi, Emanuele ;
Camisasca, Riccardo Paolo ;
Collober, Carole ;
Rochotte, Erika ;
Garber, Alan J. .
DIABETES CARE, 2007, 30 (04) :890-895
[5]   Alpha cell function in health and disease:: influence of glucagon-like peptide-1 [J].
Dunning, BE ;
Foley, JE ;
Ahrén, B .
DIABETOLOGIA, 2005, 48 (09) :1700-1713
[6]   Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes [J].
Fonseca, V. ;
Schweizer, A. ;
Albrecht, D. ;
Baron, M. A. ;
Chang, I. ;
Dejager, S. .
DIABETOLOGIA, 2007, 50 (06) :1148-1155
[7]   Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study [J].
Garber, A. J. ;
Schweizer, A. ;
Baron, M. A. ;
Rochotte, E. ;
Dejager, S. .
DIABETES OBESITY & METABOLISM, 2007, 9 (02) :166-174
[8]   Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness [J].
Henderson, JN ;
Allen, KV ;
Deary, IJ ;
Frier, BM .
DIABETIC MEDICINE, 2003, 20 (12) :1016-1021
[9]   Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes [J].
Mari, A ;
Sallas, WM ;
He, YL ;
Watson, C ;
Ligueros-Saylan, M ;
Dunning, BE ;
Deacon, CF ;
Holst, JJ ;
Foley, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4888-4894
[10]   Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men [J].
Matyka, K ;
Evans, M ;
Lomas, J ;
Cranston, I ;
Macdonald, I ;
Amiel, SA .
DIABETES CARE, 1997, 20 (02) :135-141
12